Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2024-12-27 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于以集中竞价方式回购股份方案的公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement regarding a company's plan to repurchase its own shares through a centralized bidding process. It includes specifics about the repurchase amount, price limits, funding sources, purposes (such as employee stock plans and capital reduction), timelines, and associated risks. The text also discusses the approval process involving the board and shareholders, and the legal and financial implications of the repurchase. This type of document is a clear report on a share buyback program, which fits the category of a Transaction in Own Shares (POS). It is not a brief announcement or a regulatory filing, but a comprehensive disclosure of the repurchase plan and its details. Therefore, the correct classification is POS with high confidence.
2024-12-27 Chinese
美迪西：关于召开2025年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2025 first extraordinary general meeting (临时股东大会) of Shanghai Medicilon Biopharmaceutical Co., Ltd. It includes information about the meeting date, voting methods, agenda items including election of board members and supervisors, voting instructions, and proxy forms. The content focuses on the announcement and procedural details of a shareholders' meeting rather than the results of voting or the meeting minutes. It does not contain financial statements, audit information, or earnings data. It is not a proxy solicitation or remuneration report. The document is not a report publication announcement since it contains substantive meeting details and instructions. The primary purpose is to notify shareholders about the meeting and the agenda for voting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since this document is a notice of the meeting and the agenda, not the actual voting results or proxy solicitation materials, it aligns best with Proxy Solicitation & Information Statement (PSI).
2024-12-27 Chinese
美迪西：第三届董事会第二十六次会议决议公告
Transaction in Own Shares Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of Shanghai Medicilon Inc. It details the approval of a share repurchase plan and the proposal to convene an extraordinary general meeting. The text includes voting results and references to further announcements on the stock exchange website. The document length is short (1116 characters) and it does not contain financial statements or detailed financial data. It is not a full report but an announcement of board decisions, specifically about share repurchase and meeting convening. This fits the category of Transaction in Own Shares (POS) because it concerns a share buyback plan approved by the board.
2024-12-27 Chinese
美迪西：独立董事候选人声明与承诺-马大为
Regulatory Filings Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate of Shanghai Medicilon Inc., detailing qualifications, independence criteria, and compliance with regulatory requirements for independent directors. It is not a financial report, earnings release, or any form of shareholder meeting material. It does not announce changes in management but is a formal statement related to board candidate qualifications. This type of document fits best under Regulatory Filings (RNS) as it is a compliance and disclosure document that does not fit other specific categories.
2024-12-24 Chinese
美迪西：独立董事候选人声明与承诺-王剑锋
Board/Management Information Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate of Shanghai Medicilon Inc. It details the candidate's qualifications, compliance with regulatory requirements, and commitment to independence and duties as an independent director. There is no financial data, no report or announcement of financial results, no voting results, no management changes, or other typical financial or regulatory filings. The document is a formal statement related to board/management information, specifically about a director candidate's qualifications and commitments. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on a single candidate's declaration, consistent with management information disclosures rather than broader reports or announcements.
2024-12-24 Chinese
美迪西：独立董事候选人声明与承诺-赖卫东
Board/Management Information Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate of Shanghai Medicilon Inc. It details the candidate's qualifications, compliance with regulatory requirements, and commitment to independence and duties. There are no financial statements, no report data, no voting results, no meeting materials, and no announcements of financial or corporate actions. The document is a formal statement related to board/management information, specifically about a director candidate's qualifications and commitments. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report but a standalone declaration.
2024-12-24 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.